Patent: 6,056,957
✉ Email this page to a colleague
Summary for Patent: 6,056,957
| Title: | Humanized monoclonal antibodies against human interleukin-5 |
| Abstract: | A monoclonal antibody is provided which specifically binds to human interleukin-5. Also provided are a hybridoma which produces the monoclonal antibody; complementary DNAs which encode the heavy and light chain variable regions of the monoclonal antibody and CDRs therefrom; humanized monoclonal antibodies; and pharmaceutical compositions comprising the monoclonal antibody or anti-idiotypic antibodies directed against it, humanized monoclonal antibodies, binding fragments, binding compositions or single-chain binding proteins derived from the antibody and a physiologically acceptable carrier. |
| Inventor(s): | Chou; Chuan-Chu (Westfield, NJ), Murgolo; Nicholas J. (Millington, NJ), Abrams; John S. (Belmont, CA), Jenh; Chung-Her (Edison, NJ), Petro; Mary E. (Green Pond, NJ), Silver; Jon E. (San Jose, CA), Tindall; Stephen (Madison, NJ), Windsor; William T. (East Brunswick, NJ), Zavodny; Paul J. (Mountainside, NJ) |
| Assignee: | Schering Corporation (Kenilworth, NJ) |
| Application Number: | 08/284,516 |
| Patent Claims: | see list of patent claims |
Details for Patent 6,056,957
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Teva Respiratory, Llc | CINQAIR | reslizumab | Injection | 761033 | 03/23/2016 | ⤷ Try a Trial | 2017-05-02 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
